NASDAQ$GILD
Gilead Sciences Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Gilead Sciences' performance reflected the strength and diversity of its business, with both HIV and oncology therapies contributing to year-over-year growth.
Gilead Sciences announced its Q1 2022 financial results, with revenue increasing by 3% to $6.6 billion. Biktarvy sales increased 18% year-over-year to $2.2 billion, and oncology sales increased 60% year-over-year to $420 million. Diluted EPS decreased to $0.02, while non-GAAP diluted EPS increased 4% to $2.12.
- First quarter 2022 revenue increased 3% to $6.6 billion compared to the same period in 2021.
- Biktarvy sales increased 18% year-over-year.
- Oncology sales increased 60% year-over-year.
- Non-GAAP diluted EPS increased 4% to $2.12.
Headline financials
Revenue & EPS history
Gilead Sciences · Revenue · Quarterly
$6.59B
Revenue by segment
Gilead Sciences · $6.14B total across 3 segments · Q3 2023
- HIV$4.67B+4.0%76.0%
- Oncology$769M+327.2%12.5%
- Liver Disease$706M—11.5%
Forward guidance
Gilead updated its EPS guidance to primarily reflect the $2.7 billion IPR&D impairment. The company now expects EPS between $3.00 and $3.50, compared to $4.70 and $5.20 previously. There is no change to other guidance shared on February 1, 2022.
Tailwinds
- Total product sales between $23.8 billion and $24.3 billion.
- Total product sales, excluding Veklury, between $21.8 billion and $22.3 billion.
- Total Veklury sales of approximately $2.0 billion.
- Non-GAAP earnings per share between $6.20 and $6.70.
- The financial guidance excludes the impact of any expenses related to potential acquisitions or business development transactions that have not been executed, fair value adjustments of equity securities and discrete tax charges or benefits associated with changes in tax related laws and guidelines as Gilead is unable to project such amounts.
Headwinds
- Uncertainty around the duration and magnitude of the COVID-19 pandemic.
- Potential adverse revenue impacts from COVID-19.
- Potential revenues from Veklury.
- The rate and degree of these impacts as well as the corresponding recovery from the pandemic may vary across Gilead’s business.
- The financial guidance is subject to a number of risks and uncertainties.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
+0.2%
Avg return
Earnings day
-0.2%
Avg return
5 days after
-0.4%
Avg return
30 days after
44%
32 / 73 earnings
Positive
+11.9%
Q3 2022
Best reaction
-12.4%
Q1 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.5% | -1.5% | -3.4% | |
| Q4 2025 | +5.8% | +5.3% | -1.5% | |
| Q3 2025 | +3.1% | +3.5% | +6.2% | |
| Q2 2025 | +8.3% | +8.9% | +4.3% | |
| Q1 2025 | -2.8% | +0.4% | +1.1% | |
| Q4 2024 | +7.5% | +8.3% | +15.9% | |
| Q3 2024 | +8.5% | +7.5% | +2.1% | |
| Q2 2024 | -0.5% | -0.0% | +6.4% | |
| Q1 2024 | -2.5% | -2.8% | -2.1% | |
| Q4 2023 | -3.0% | -4.0% | -4.0% | |
| Q3 2023 | -4.0% | -6.4% | -3.8% | |
| Q2 2023 | +4.0% | +5.8% | +1.3% | |
| Q1 2023 | -1.8% | -3.9% | -7.9% | |
| Q4 2022 | +0.6% | +2.4% | -3.5% | |
| Q3 2022 | +11.9% | +12.0% | +21.8% | |
| Q2 2022 | +4.5% | +2.5% | +9.0% | |
| Q1 2022 | -3.7% | -2.0% | +5.2% | |
| Q4 2021 | -4.2% | -7.0% | -10.1% | |
| Q3 2021 | -2.8% | -1.3% | +5.2% | |
| Q2 2021 | -2.5% | -0.3% | +1.7% | |
| Q1 2021 | -1.5% | +1.9% | +2.6% | |
| Q4 2020 | +6.1% | +4.3% | +0.2% | |
| Q3 2020 | -2.5% | -2.5% | +0.0% | |
| Q2 2020 | -4.8% | -2.9% | -10.6% | |
| Q1 2020 | -3.8% | -4.8% | -6.4% | |
| Q4 2019 | -0.7% | +3.8% | +14.7% | |
| Q3 2019 | -4.9% | -4.7% | -2.0% | |
| Q2 2019 | -3.5% | -4.3% | -6.1% | |
| Q1 2019 | +3.5% | +2.4% | -4.0% | |
| Q4 2018 | -3.4% | -3.7% | -10.2% | |
| Q3 2018 | +2.5% | +5.9% | -2.1% | |
| Q2 2018 | +0.7% | -1.7% | -5.2% | |
| Q1 2018 | -7.4% | -9.4% | -6.7% | |
| Q4 2017 | +5.6% | +1.2% | +2.2% | |
| Q3 2017 | -3.5% | -6.2% | -9.3% | |
| Q2 2017 | +1.7% | +3.2% | +0.1% | |
| Q1 2017 | -1.3% | -0.5% | -5.1% | |
| Q4 2016 | -7.7% | -8.3% | -5.5% | |
| Q3 2016 | -1.5% | -1.6% | -1.1% | |
| Q2 2016 | -6.4% | -8.2% | -7.0% | |
| Q1 2016 | -12.4% | — | — | |
| Q4 2015 | +2.8% | — | — | |
| Q3 2015 | -0.5% | — | — | |
| Q2 2015 | +4.7% | — | — | |
| Q1 2015 | +2.6% | — | — | |
| Q4 2014 | -7.3% | — | — | |
| Q3 2014 | -1.7% | — | — | |
| Q2 2014 | +1.4% | — | — | |
| Q1 2014 | +3.2% | — | — | |
| Q4 2013 | -0.9% | — | — | |
| Q3 2013 | +5.7% | — | — | |
| Q2 2013 | +4.5% | — | — | |
| Q1 2013 | +10.0% | — | — | |
| Q4 2012 | -0.0% | — | — | |
| Q3 2012 | +3.0% | — | — | |
| Q2 2012 | +8.4% | — | — | |
| Q1 2012 | -0.8% | — | — | |
| Q4 2011 | +1.6% | — | — | |
| Q3 2011 | +0.4% | — | — | |
| Q2 2011 | -1.6% | — | — | |
| Q1 2011 | +0.4% | — | — | |
| Q4 2010 | -1.1% | — | — | |
| Q3 2010 | -1.2% | — | — | |
| Q2 2010 | -0.1% | — | — | |
| Q1 2009 | +2.3% | — | — | |
| Q1 2010 | +0.0% | — | — | |
| Q4 2007 | -0.2% | — | — | |
| Q4 2009 | -0.2% | — | — | |
| Q3 2009 | +5.4% | — | — | |
| Q3 2008 | +5.4% | — | — | |
| Q4 2008 | -5.0% | — | — | |
| Q2 2008 | -5.0% | — | — | |
| Q2 2009 | -5.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro